登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002342 证券简称：巨力索具 公告编号：2025-067 巨力索具股份有限公司 关于收到河北证监局行政监管措施 决定书整改的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 巨力索具股份有限公司（以下简称"公司"）于2025年12月18日收到中国证券监督管理委员会河北监管局 （以下简称"河北证监局"）下发的（〔2025〕43号）《河北证监局关于对巨力索具股份有限公司采取责 令改正并出具警示函、对相关责任人采取监管谈话的行政监管措施的决定》（以下简称"《决定 书》"）。公司董事会及管理层对此高度重视，诚恳接受河北证监局的行政监管措施，并深刻反思。收 到《决定书》后，公司立即组织董事、高级管理人员及相关责任部门进行了专题学习，深入剖析问题根 源，并制定了系统性整改方案。现将整改情况公告如下： 一、 整改措施的总体安排 为了更好地落实河北证监局相关要求，公司董事、高级管理人员以及相关部门人员,本着实事求是的原 则,严格按照法律、法规和规范性文件以及《公司章程》及公司相关制度的要求，对《决定书》中提出 ...

Core Viewpoint - Jiangsu Zhongshe Group Co., Ltd. (stock code: 002883) announced that its controlling shareholder's action partner, Wuxi Juhang Investment Partnership, received warning letters from the Jiangsu Securities Regulatory Bureau and the Shenzhen Stock Exchange for failing to comply with regulations during a share acquisition process [1][2]. Group 1 - Wuxi Juhang Investment increased its shareholding in Zhongshe Group from 24.63% to 25.62% between September 24 and September 30, 2025, without halting trading when the combined shareholding reached 25% [2]. - The actions of Wuxi Juhang Investment violated the regulations outlined in the "Measures for the Administration of Acquisitions of Listed Companies," specifically regarding the requirement to stop trading and disclose changes in equity when reaching a certain shareholding threshold [2][3]. - The Jiangsu Securities Regulatory Bureau issued a warning letter based on the violation, and Wuxi Juhang Investment is required to submit a written report within 10 working days [3]. Group 2 - The Shenzhen Stock Exchange highlighted that Wuxi Juhang Investment's actions contravened multiple articles of the "Stock Listing Rules (2025 Revision)," emphasizing the need for compliance in stock trading and timely information disclosure [3]. - Wuxi Juhang Investment expressed its commitment to enhancing compliance awareness and adhering to relevant laws and regulations to prevent future violations [3]. - Zhongshe Group reassured investors that the regulatory matters would not impact its normal production and operational activities [3].

Core Viewpoint - The recent penalty imposed on Jincheng Pharmaceutical's actual controller and chairman, Zhao Yeqing, for manipulating the securities market highlights a lack of compliance awareness among the company's core members and reflects long-standing governance issues within the company, leading to a dual crisis of trust and development for the firm [1][4]. Regulatory Actions - In August of last year, Zhao Yeqing received a notice from the CSRC regarding an investigation into his alleged market manipulation, coinciding with a significant stock reduction by his father, Zhao Hongfu, which raised market suspicions about the motives behind the sell-off [2]. - The penalty announced in September this year significantly reduced the initial proposed fines from March, where Zhao was to forfeit illegal gains of 7.72 million yuan and face a fine of 23.16 million yuan, totaling 30.88 million yuan, to a mere fine of 1.5 million yuan, while maintaining a four-year market ban [2][3]. Company Performance - Jincheng Pharmaceutical has been experiencing a decline in both revenue and profit, with a reported revenue of 1.36 billion yuan in the first half of 2025, down 22.65% year-on-year, and a net profit of 43.38 million yuan, down 66.78% [6]. - The company's core product, the cephalosporin side-chain active ester series, saw a revenue decline of 32.20%, while the formulation products dropped by 29.04%, indicating a significant downturn in its primary revenue sources [6][7]. Financial Metrics - The company's gross profit margin fell to 36.13% in the first half of 2025, a decrease of approximately 4.49 percentage points from the previous year, with all major product lines experiencing a decline in gross margin [7]. - Jincheng Pharmaceutical's R&D investment as a percentage of revenue has been significantly lower than the industry average, with figures of 7.87% and 5.68% in 2023 and 2024, respectively, compared to the industry averages of 12.34% and 12.61% [9]. Strategic Challenges - The company has struggled with a lack of clear strategic direction, failing to effectively transition from its reliance on intermediate products to a more diversified portfolio, which has hindered its ability to adapt to industry trends towards innovative drugs and high-end formulations [11]. - Jincheng Pharmaceutical's international market expansion has also been slow, with overseas revenue declining from 774 million yuan in 2019 to 685 million yuan in 2024, and further down to 708 million yuan in the first half of 2025, indicating a loss of market share [12].